NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Cash from Discontinued Operations of 26460000.0 for Q3 2024, up 178.66% quarter-over-quarter from 33640206.31 in Q3 2020.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Cash from Discontinued Operations for 2 consecutive years, with 26460000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Cash from Discontinued Operations changed N/A year-over-year to 26460000.0; the TTM figure through Dec 2025 stood at 26460000.0 (changed N/A YoY), while the FY2024 annual figure was 27498000.0, up 74.95% from the prior year.
- Cash from Discontinued Operations grew to 26460000.0 in Q3 2024 per NBP's latest filing, from 33640206.31 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 26460000.0 in Q3 2024 and bottomed at 33640206.31 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 7.84 Mn |
| Sep 30, 2024 | 26.46 Mn |
| Sep 30, 2020 | -33.64 Mn |
| Dec 31, 2019 | -30.64 Mn |